A new study has found that the diabetes drug tirzepatide helps people lower their blood sugar and lose weight more quickly ...

There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds, lower heart-disease risk, manage obstructive sleep apnea, and more. But as more people use these drugs ...

The injectable drugs have been in shortage since 2022 ... Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, tirzepatide.

The Poison Center is reporting a “surge” of incoming calls about accidental overdosing of popular injectable drugs used for weight loss and diabetes management.

And because these are relatively new medications, more research is needed to accurately compare the oral and injectable versions. The 2021 review looked specifically at people with diabetes who ...

Learn more about diabetes medications. Medicare Part B covers ... Prescription drug plans, such as Part D, cover injectable insulin and related supplies, including syringes, needles, and gauze.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5-7% of their weight had a 58% lower risk of developing it.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.